Modulation of microglial phenotypes by dexmedetomidine through TREM2 reduces neuroinflammation in heatstroke
Abstract No FDA approved pharmacological therapy is available to reduce neuroinflammation following heatstroke. Previous studies have indicated that dexmedetomidine (DEX) could protect against inflammation and brain injury in various inflammation-associated diseases. However, no one has tested wheth...
Guardado en:
Autores principales: | Ping Li, Tingting Shen, Xue Luo, Ju Yang, Zhen Luo, Yulong Tan, Genlin He, Zeze Wang, Xueting Yu, Ying Wang, Xuesen Yang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ffffee16cf03490599b2fb08328301bf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Modulation of microglial phenotypes by dexmedetomidine through TREM2 reduces neuroinflammation in heatstroke
por: Ping Li, et al.
Publicado: (2021) -
Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model
por: Li Zhong, et al.
Publicado: (2019) -
Electromagnetic field exposure-induced depression features could be alleviated by heat acclimation based on remodeling the gut microbiota
por: Xue Luo, et al.
Publicado: (2021) -
Author Correction: Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model
por: Li Zhong, et al.
Publicado: (2019) -
LPS-induced proNGF synthesis and release in the N9 and BV2 microglial cells: a new pathway underling microglial toxicity in neuroinflammation.
por: Li Duan, et al.
Publicado: (2013)